NCT05760287 Echocardiographic Characterization of Cardiac Amyloidosis
| NCT ID | NCT05760287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Cardiac Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 255 participants |
| Start Date | 2022-12-09 |
| Primary Completion | 2030-12-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 255 participants in total. It began in 2022-12-09 with a primary completion date of 2030-12-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled. The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype. Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.
Eligibility Criteria
Inclusion Criteria: * patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit. Exclusion Criteria: * missing data * decline to the study participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05760287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05760287 currently recruiting?
Yes, NCT05760287 is actively recruiting participants. Contact the research team at francesca.graziani@policlinicogemelli.it for enrollment information.
Where is the NCT05760287 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT05760287 clinical trial?
NCT05760287 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 255 participants.